227 related articles for article (PubMed ID: 33314351)
1. The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings.
Skrahina V; Gaber H; Vollstedt EJ; Förster TM; Usnich T; Curado F; Brüggemann N; Paul J; Bogdanovic X; Zülbahar S; Olmedillas M; Skobalj S; Ameziane N; Bauer P; Csoti I; Koleva-Alazeh N; Grittner U; Westenberger A; Kasten M; Beetz C; Klein C; Rolfs A;
Mov Disord; 2021 Apr; 36(4):1005-1010. PubMed ID: 33314351
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
[TBL] [Abstract][Full Text] [Related]
3. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
[TBL] [Abstract][Full Text] [Related]
4. Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Glinka T; Goldstein O; Kestenbaum M; Cedarbaum JM; Mabrouk OS; Fraser KB; Shirvan JC; Orr-Urtreger A; Mirelman A; Thaler A
Mov Disord; 2022 Jan; 37(1):190-195. PubMed ID: 34550621
[TBL] [Abstract][Full Text] [Related]
5. Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study.
Tropea TF; Amari N; Han N; Rick J; Suh E; Akhtar RS; Dahodwala N; Deik A; Gonzalez-Alegre P; Hurtig H; Siderowf A; Spindler M; Stern M; Thenganatt MA; Weintraub D; Willis AW; Van Deerlin V; Chen-Plotkin A
J Parkinsons Dis; 2021; 11(2):757-765. PubMed ID: 33492247
[TBL] [Abstract][Full Text] [Related]
6. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
7. LRRK2, GBA and SMPD1 Founder Mutations and Parkinson's Disease in Ashkenazi Jews.
Dagan E; Schlesinger I; Kurolap A; Ayoub M; Nassar M; Peretz-Aharon J; Gershoni-Baruch R
Dement Geriatr Cogn Disord; 2016; 42(1-2):1-6. PubMed ID: 27449028
[TBL] [Abstract][Full Text] [Related]
8. Progression in the LRRK2-Asssociated Parkinson Disease Population.
Saunders-Pullman R; Mirelman A; Alcalay RN; Wang C; Ortega RA; Raymond D; Mejia-Santana H; Orbe-Reilly M; Johannes BA; Thaler A; Ozelius L; Orr-Urtreger A; Marder KS; Giladi N; Bressman SB;
JAMA Neurol; 2018 Mar; 75(3):312-319. PubMed ID: 29309488
[TBL] [Abstract][Full Text] [Related]
9. Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes.
Thaler A; Kozlovski T; Gurevich T; Bar-Shira A; Gana-Weisz M; Orr-Urtreger A; Giladi N; Mirelman A
Mov Disord; 2018 Oct; 33(10):1656-1660. PubMed ID: 30288804
[TBL] [Abstract][Full Text] [Related]
10. PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease.
Noyce AJ; R'Bibo L; Peress L; Bestwick JP; Adams-Carr KL; Mencacci NE; Hawkes CH; Masters JM; Wood N; Hardy J; Giovannoni G; Lees AJ; Schrag A
Mov Disord; 2017 Feb; 32(2):219-226. PubMed ID: 28090684
[TBL] [Abstract][Full Text] [Related]
11. Variants in PSMB9 and FGR differentially affect Parkinson's disease risk in GBA and LRRK2 mutation carriers.
Shani S; Goldstein O; Gana-Weisz M; Bar-Shira A; Thaler A; Gurevich T; Mirelman A; Giladi N; Alcalay RN; Orr-Urtreger A
Parkinsonism Relat Disord; 2023 Jun; 111():105398. PubMed ID: 37116292
[TBL] [Abstract][Full Text] [Related]
12. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease.
da Silva CP; de M Abreu G; Cabello Acero PH; Campos M; Pereira JS; de A Ramos SR; Nascimento CM; Voigt DD; Rosso AL; Araujo Leite MA; Vasconcellos LFR; Nicaretta DH; Della Coletta MV; da Silva DJ; Gonçalves AP; Dos Santos JM; Calassara V; Valença DCT; de M Martins CJ; Santos-Rebouças CB; Pimentel MMG
J Neurol Sci; 2017 Oct; 381():160-164. PubMed ID: 28991672
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of pre-diagnostic symptoms did not differ between LRRK2-related, GBA-related and idiopathic patients with Parkinson's disease.
Liu SY; Zheng Z; Gu ZQ; Wang CD; Tang BS; Xu YM; Ma JH; Zhou YT; Feng T; Chen SD; Chan P;
Parkinsonism Relat Disord; 2018 Dec; 57():72-76. PubMed ID: 30119933
[TBL] [Abstract][Full Text] [Related]
14. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.
Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A
Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835
[TBL] [Abstract][Full Text] [Related]
15. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
[TBL] [Abstract][Full Text] [Related]
16. Genetic heterogeneity on sleep disorders in Parkinson's disease: a systematic review and meta-analysis.
Huang J; Cheng Y; Li C; Shang H
Transl Neurodegener; 2022 Apr; 11(1):21. PubMed ID: 35395825
[TBL] [Abstract][Full Text] [Related]
17. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
18. An Exploratory Study Using Electronic Medical Records to Assess the Feasibility of Establishing Cohorts of Patients with Genetic Causes of Parkinson's Disease.
Lee SJ; Shaw PM; Thornton B; Kumar A; Eizik M; Goldstaub D; Braun T; Teper G; Pai JK; Chodick G; Bienfait K; Levitan D; Beller D; Chris Min K; Jonathan D; Voss T; Fox CS; Aubrey Stoch S; Struyk AF; Vainstein G
J Parkinsons Dis; 2022; 12(5):1645-1653. PubMed ID: 35466950
[TBL] [Abstract][Full Text] [Related]
19. Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease.
Toffoli M; Higgins A; Lee C; Koletsi S; Chen X; Eberle M; Sedlazeck FJ; Mullin S; Proukakis C; Schapira AHV
Mov Disord; 2021 Jun; 36(6):1456-1460. PubMed ID: 34008887
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin.
Senkevich K; Rudakou U; Gan-Or Z
Neuropharmacology; 2022 Jan; 202():108822. PubMed ID: 34626666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
